We are very pleased to announce that Matthias Krieger will take over the role of Managing Director of FinVector Oy, effective 22nd April 2023.
Matthias will succeed Tal Levy, who will concentrate on the development and growth of Ferring-BTG (Israel), where he has served as General Manager since 2016, in parallel to his responsibilities as Managing Director of FinVector Oy since 2022.
Matthias Krieger (left) and Tal Levy (right).
Matthias is a seasoned manufacturing executive and hands-on leader: His industrial career led him through R&D, (pre)clinical supply in Technical R&D, biotech start-up to full-scale commercial manufacturing, which will be crucial for the product launch and commercialization of Adstiladrin®. Most of his 20+ years in the pharmaceutical industry have been spent with Novartis in different leadership roles in Switzerland and the United States.
“I am very excited to join FinVector and look forward to getting to know the Team and the Site in Kuopio over the next couple of weeks. We have an amazing journey ahead of us to bring a world-class, breakthrough gene therapy to the market. I feel privileged to be part of this journey with a great team that has taken the science to this level. There will be plenty of challenges to overcome, but together we will change many lives. Many of us have family or friends who have battled cancer. Therefore, I am sure the patient will be at the forefront for all of us, in everything we do. I very much look forward to partnering and working with all of you.”
Matthias holds a PhD in Chemistry and has conducted post-doctoral studies in Japan. Having grown up in a working-class family in Southern Germany, Matthias very much values high-quality of work at all levels of the organization. Matthias is married and has a lively three-year-old son. An avid mountain biker, hiker and cross country-skier, he is excited to explore the Finnish outdoors with his family in his spare time.
We would like to thank Tal Levy for his valuable contribution and dedication to FinVector Oy and Ferring-BTG for the past two years. Thanks to his thorough experience gained over many years within the Ferring Group, Tal has succeeded in building bridges between FinVector Oy and Ferring Pharmaceuticals, enhancing the collaboration between teams. Under his unique leadership, Tal has brought FinVector Oy to the next level, culminating with the FDA approval for Adstiladrin®.
“I want to thank the board and the chairman of the board for their trust and the opportunity to lead FVT during this special time where the company shifted from an R&D company to a commercial one, helping build its foundations and connections to Ferring for the future. I had an amazing opportunity to work with highly talented people and support the journey of Adstiladrin®, thank you all.”
Tal began his career at Ferring-BTG in 2006 and has served as General Manager since 2016. Under Tal’s leadership, BTG has become a forward-looking innovative part of Ferring, focusing on GMP operational excellence through the highest professional standards and business-oriented integrated R&D at the site.
Tal holds a BSc in Industrial & Management Engineering from Ben-Gurion University, an MA in Law Studies from Bar-Ilan University, and an MBA in Healthcare Innovation from IDC Reichman University.
Please join us in wishing Matthias and Tal every success in their respective roles.
Jean-Frédéric Paulsen
Chairman, Ferring Ventures SA and
Chairman, FinVector Oy
Member of the Board, Ferring Pharmaceuticals